XML 116 R28.htm IDEA: XBRL DOCUMENT v3.25.1
INCOME TAXES (Tables)
12 Months Ended
Jun. 30, 2024
Income Tax Disclosure [Abstract]  
SCHEDULE OF INCOME TAX PROVISION

The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2024 and 2023 is as follows:

 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024 and 2023

US  June 30, 2024   June 30, 2023 
   Year Ended 
US  June 30, 2024   June 30, 2023 
Loss before Income taxes  $(1,874,914)  $(2,790,407)
           
Taxes under statutory US tax rates  $(393,732)  $(585,986)
Increase (decrease) in valuation allowance   306,682    556,521 
Foreign tax rate differential   (55,358)   (60,316)
Prior period adjustment   76,194    81,599 
Other   66,214    8,182 
Income tax (expense) benefit  $-   $- 
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES
   June 30, 2024   June 30, 2023 
   Year Ended 
   June 30, 2024   June 30, 2023 
Deferred tax assets          
Warrant Derivative Liability  $513,071   $579,544 
Accrued Expenses   559,723    478,273 
Prepaid Investor Services   551,796    575,021 
Non-cash interest   817,536    758,797 
Intangibles (Intellectual Property and Patent Cost)   351,144    321,557 
Deferred Rent   4,492    4,550 
Formation Expense   6,553    6,553 
Net Operating Loss carryforward   9,075,029    8,910,874 
Gain on extinguishment of debt   97,992    47,393 
Stock Based Compensation   84,028    84,028 
Total Deferred tax assets  $12,061,364   $11,766,590 
           
Deferred tax liabilities          
Research and Development  $(170,435)  $(202,568)
Foreign Exchange Loss (OCI)   (39,379)   (39,379)
Capital Raising Costs   (389,258)   (369,033)
Total deferred tax liabilities  $(599,072)  $(610,980)
           
Net deferred tax assets  $11,462,292   $11,155,610 
Valuation allowance   (11,462,292)   (11,155,610)
Net deferred tax assets  $-   $- 
SCHEDULE OF LOSS PER SHARE BASIS OF REVERSE STOCK SPLIT

The unaudited pro forma tables below show the losses per share prior to the reverse split and following the reverse split. A key assumption to the loss per share calculation is that post-reverse split price is equal to the pre-reverse split times the number of shares from the ratio.

 

Historical per share data – (Pre- Split basis) 

Year Ended

June 30, 2024

  

Year Ended

June 30, 2023

 
         
Net loss available to Common Stockholders  $2,013,488   $3,126,839 
Basic and diluted weighted average shares outstanding   85,045,339    1,738,802 
Basic and diluted net loss per share  $0.02   $1.80 

 

The assumption inherent in the table below is a reverse split of 1:100,000.

 

Historical per share data – (Post- Split basis) 

Year Ended

June 30, 2024

  

Year Ended

June 30, 2023

 
         
Net loss available to Common Stockholders  $2,013,488   $3,126,839 
Basic and diluted weighted average shares outstanding   850    17 
Basic and diluted net loss per share  $2,368.81   $183,931.71 

 

The table below shows the loss per share effect of reverse stock splits at 1:10,000, 1:50,000 and 1:100,000:

 

   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
 
Split Ratio  1:10,000   1:50,000   1:100,000 
   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
   Year Ended
June 30, 2024
   Year Ended
June 30, 2023
 
Net losses available to common stockholders  $2,013,488   $3,126,839   $2,013,488   $3,126,839   $2,013,488   $3,126,839 
Weighted Average Shares Outstanding   8,505    174    1,701    35    850    17 
Loss per share  $236.74   $17,970   $1,183.71   $89,338.26   $2,368.81   $183,931.71